Characterization of structural domains of human osteoclastogenesis inhibitory factor

被引:175
作者
Yamaguchi, K
Kinosaki, M
Goto, M
Kobayashi, F
Tsuda, E
Morinaga, T
Higashio, K
机构
[1] Research Institute of Life Science, Snow Brand Milk Products Co., Ltd., Shimotsuga-gun, Tochigi 329-0512
关键词
D O I
10.1074/jbc.273.9.5117
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Osteoclastogenesis inhibitory factor (OCIF) is a heparin-binding secretary glycoprotein that belongs to the tumor necrosis factor receptor (TNFR) family. OCIF is present both as a similar to 60-kDa monomer and a disulfide-linked homodimer, We attempted to characterize the seven structural domains of OCIF by determining the capabilities of various OCIF mutants to inhibit osteoclastogenesis, to interact with heparin, and to form dimers. We also examined a potential of domains 5 and 6, death domain homologous regions (DDHs), for inducing cell death by expressing OCIF/Fas fusion proteins, Our results show that: (i) the N-terminal portion of OCIF containing domains 1-4, which have structural similarity to the extracellular domains of the TNFR family proteins, is sufficient to inhibit osteoclastogenesis; (ii) a heparin-binding site is located in domain 7, and affinity for heparin does not correlate with the inhibitory activity; (iii) Cys-400 in domain 7 is the residue responsible for dimer formation; and (iv) the C-terminal portion containing domains 5 and 6, DDHs, has a high potential for mediating a cytotoxic signal when it is expressed in cells as an OCIF/Fas fusion protein in which the transmembrane region of Fas is inserted in front of DDHs.
引用
收藏
页码:5117 / 5123
页数:7
相关论文
共 29 条
[1]   PROTECTION AGAINST ENDOTOXIC-SHOCK BY A TUMOR-NECROSIS-FACTOR RECEPTOR IMMUNOADHESIN [J].
ASHKENAZI, A ;
MARSTERS, SA ;
CAPON, DJ ;
CHAMOW, SM ;
FIGARI, IS ;
PENNICA, D ;
GOEDDEL, DV ;
PALLADINO, MA ;
SMITH, DH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (23) :10535-10539
[2]   TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas(Apo-1/CD95) [J].
Bodmer, JL ;
Burns, K ;
Schneider, P ;
Hofmann, K ;
Steiner, V ;
Thome, M ;
Bornand, T ;
Hahne, M ;
Schroter, M ;
Becker, K ;
Wilson, A ;
French, LE ;
Browning, JL ;
MacDonald, HR ;
Tschopp, J .
IMMUNITY, 1997, 6 (01) :79-88
[3]   MOLECULAR MODELING OF PROTEIN-GLYCOSAMINOGLYCAN INTERACTIONS [J].
CARDIN, AD ;
WEINTRAUB, HJR .
ARTERIOSCLEROSIS, 1989, 9 (01) :21-32
[4]  
CHAMBERS TJ, 1991, VITAM HORM, V46, P41
[5]   PROTECTION FROM FAS-MEDIATED APOPTOSIS BY A SOLUBLE FORM OF THE FAS MOLECULE [J].
CHENG, JH ;
ZHOU, T ;
LIU, CD ;
SHAPIRO, JP ;
BRAUER, MJ ;
KIEFER, MC ;
BARR, PJ ;
MOUNTZ, JD .
SCIENCE, 1994, 263 (5154) :1759-1762
[6]   Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95 [J].
Chinnaiyan, AM ;
ORourke, K ;
Yu, GL ;
Lyons, RH ;
Garg, M ;
Duan, DR ;
Xing, L ;
Gentz, R ;
Ni, J ;
Dixit, VM .
SCIENCE, 1996, 274 (5289) :990-992
[7]   CONTENDERS IN FASL/TNF DEATH SIGNALING [J].
CLEVELAND, JL ;
IHLE, JN .
CELL, 1995, 81 (04) :479-482
[8]   RAIDD is a new 'death' adaptor molecule [J].
Duan, H ;
Dixit, VM .
NATURE, 1997, 385 (6611) :86-89
[9]  
HARTMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506
[10]  
ITOH N, 1993, J BIOL CHEM, V268, P10932